Press Release Archive
-
Johnson & Johnson to Host Investor Conference Call on Third Quarter ResultsJohnson & Johnson to Host Investor Conference Call on Third Quarter Results
-
New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)OPTIMUM Phase 3 study data presented for the first time during oral presentation at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis
-
DePuy Synthes Expands ATTUNE Knee Platform with Cementless OptionDePuy Synthes Expands ATTUNE Knee Platform with Cementless OptionCementless technology supports growing trend of younger, more active patients undergoing knee replacement
-
New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with IntentNew Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with IntentGlobal clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies
-
Johnson & Johnson Announces Six Winners of the Champions of Science Africa Innovation Challenge 2.0 at the 28th World Economic Forum on AfricaJohnson & Johnson Announces Six Winners of the Champions of Science Africa Innovation Challenge 2.0 at the 28th World Economic Forum on Africa
-
Johnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to ZimbabweJohnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to Zimbabwe
-
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older AdultsJanssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults
-
Johnson & Johnson To Appeal Flawed Opioid Judgment in OklahomaJohnson & Johnson To Appeal Flawed Opioid Judgment in OklahomaCompany did not cause opioid crisis; neither facts nor law support this outcomeCompany confident it has strong grounds for appeal
-
Johnson & Johnson Now Accepting Global Applications for 2020 Women in STEM2D Scholars AwardJohnson & Johnson Now Accepting Global Applications for 2020 Women in STEM2D Scholars Award
-
Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two MonthsJanssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months